Handelsbanken Fonder AB trimmed its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 33.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,300 shares of the biotechnology company’s stock after selling 2,200 shares during the period. Handelsbanken Fonder AB’s holdings in Enanta Pharmaceuticals were worth $306,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC lifted its holdings in Enanta Pharmaceuticals by 86.7% in the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 182 shares in the last quarter. C M Bidwell & Associates Ltd. purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth about $85,000. Point72 Hong Kong Ltd purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth about $114,000. KBC Group NV purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter worth about $113,000. Finally, Mutual of America Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 6.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 2,629 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 170 shares during the period. 97.09% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on ENTA shares. JMP Securities increased their price objective on shares of Enanta Pharmaceuticals from $103.00 to $137.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 9th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 10th. SVB Leerink increased their target price on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a “market perform” rating in a research report on Monday, August 1st. Robert W. Baird dropped their target price on shares of Enanta Pharmaceuticals from $130.00 to $90.00 and set an “outperform” rating for the company in a research report on Thursday, May 19th. Finally, Royal Bank of Canada dropped their target price on shares of Enanta Pharmaceuticals from $67.00 to $66.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 9th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $78.63.
Enanta Pharmaceuticals Stock Down 1.1 %
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last released its earnings results on Monday, August 8th. The biotechnology company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.17). The business had revenue of $19.48 million for the quarter, compared to analysts’ expectations of $20.73 million. Enanta Pharmaceuticals had a negative net margin of 134.21% and a negative return on equity of 32.42%. The business’s quarterly revenue was down 9.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.19) earnings per share. On average, equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.75 earnings per share for the current year.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.